Logo image of ILU.DE

ILLUMINA INC (ILU.DE) Stock Fundamental Analysis

FRA:ILU - Deutsche Boerse Ag - US4523271090 - Common Stock - Currency: EUR

82.05  -3.6 (-4.2%)

Fundamental Rating

5

ILU gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 16 industry peers in the Life Sciences Tools & Services industry. ILU is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. ILU has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year ILU was profitable.
ILU had a positive operating cash flow in the past year.
In multiple years ILU reported negative net income over the last 5 years.
Each year in the past 5 years ILU had a positive operating cash flow.
ILU.DE Yearly Net Income VS EBIT VS OCF VS FCFILU.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B -1B -2B -3B -4B

1.2 Ratios

ILU has a worse Return On Assets (-15.61%) than 93.75% of its industry peers.
ILU has a worse Return On Equity (-40.75%) than 93.75% of its industry peers.
Looking at the Return On Invested Capital, with a value of 13.57%, ILU belongs to the top of the industry, outperforming 93.75% of the companies in the same industry.
Industry RankSector Rank
ROA -15.61%
ROE -40.75%
ROIC 13.57%
ROA(3y)-22.28%
ROA(5y)-10.63%
ROE(3y)-46.16%
ROE(5y)-23.48%
ROIC(3y)N/A
ROIC(5y)N/A
ILU.DE Yearly ROA, ROE, ROICILU.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60

1.3 Margins

ILU's Operating Margin of 21.07% is amongst the best of the industry. ILU outperforms 87.50% of its industry peers.
In the last couple of years the Operating Margin of ILU has declined.
ILU has a Gross Margin of 66.34%. This is amongst the best in the industry. ILU outperforms 100.00% of its industry peers.
ILU's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 21.07%
PM (TTM) N/A
GM 66.34%
OM growth 3YN/A
OM growth 5Y-11.47%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.07%
GM growth 5Y-1.23%
ILU.DE Yearly Profit, Operating, Gross MarginsILU.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

7

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), ILU is creating some value.
The number of shares outstanding for ILU remains at a similar level compared to 1 year ago.
Compared to 5 years ago, ILU has more shares outstanding
The debt/assets ratio for ILU is higher compared to a year ago.
ILU.DE Yearly Shares OutstandingILU.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
ILU.DE Yearly Total Debt VS Total AssetsILU.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.2 Solvency

An Altman-Z score of 3.69 indicates that ILU is not in any danger for bankruptcy at the moment.
ILU has a Altman-Z score of 3.69. This is in the better half of the industry: ILU outperforms 68.75% of its industry peers.
ILU has a debt to FCF ratio of 2.27. This is a good value and a sign of high solvency as ILU would need 2.27 years to pay back of all of its debts.
ILU has a Debt to FCF ratio of 2.27. This is amongst the best in the industry. ILU outperforms 93.75% of its industry peers.
ILU has a Debt/Equity ratio of 0.63. This is a neutral value indicating ILU is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.63, ILU is doing worse than 62.50% of the companies in the same industry.
Even though the debt/equity ratio score it not favorable for ILU, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.63
Debt/FCF 2.27
Altman-Z 3.69
ROIC/WACC1.33
WACC10.22%
ILU.DE Yearly LT Debt VS Equity VS FCFILU.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B 6B 8B 10B

2.3 Liquidity

ILU has a Current Ratio of 1.86. This is a normal value and indicates that ILU is financially healthy and should not expect problems in meeting its short term obligations.
ILU has a Current ratio of 1.86. This is amongst the best in the industry. ILU outperforms 81.25% of its industry peers.
ILU has a Quick Ratio of 1.48. This is a normal value and indicates that ILU is financially healthy and should not expect problems in meeting its short term obligations.
With an excellent Quick ratio value of 1.48, ILU belongs to the best of the industry, outperforming 87.50% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.86
Quick Ratio 1.48
ILU.DE Yearly Current Assets VS Current LiabilitesILU.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 278.41% over the past year.
ILU shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -17.93% yearly.
The Revenue has decreased by -3.47% in the past year.
The Revenue has been growing slightly by 4.29% on average over the past years.
EPS 1Y (TTM)278.41%
EPS 3Y-25.65%
EPS 5Y-17.93%
EPS Q2Q%977.78%
Revenue 1Y (TTM)-3.47%
Revenue growth 3Y-1.15%
Revenue growth 5Y4.29%
Sales Q2Q%-3.25%

3.2 Future

Based on estimates for the next years, ILU will show a very strong growth in Earnings Per Share. The EPS will grow by 21.99% on average per year.
Based on estimates for the next years, ILU will show a small growth in Revenue. The Revenue will grow by 3.86% on average per year.
EPS Next Y76.08%
EPS Next 2Y39.37%
EPS Next 3Y30.46%
EPS Next 5Y21.99%
Revenue Next Year-2.13%
Revenue Next 2Y0.45%
Revenue Next 3Y2.3%
Revenue Next 5Y3.86%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
ILU.DE Yearly Revenue VS EstimatesILU.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B
ILU.DE Yearly EPS VS EstimatesILU.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2 4 6 8 10

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 28.99, which means the current valuation is very expensive for ILU.
Based on the Price/Earnings ratio, ILU is valued a bit cheaper than 62.50% of the companies in the same industry.
ILU is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.45, which is the current average of the S&P500 Index.
ILU is valuated rather expensively with a Price/Forward Earnings ratio of 20.31.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ILU is on the same level as its industry peers.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.90, ILU is valued at the same level.
Industry RankSector Rank
PE 28.99
Fwd PE 20.31
ILU.DE Price Earnings VS Forward Price EarningsILU.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ILU is valued a bit cheaper than the industry average as 68.75% of the companies are valued more expensively.
ILU's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. ILU is cheaper than 75.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 17.47
EV/EBITDA 13.51
ILU.DE Per share dataILU.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20

4.3 Compensation for Growth

ILU's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ILU's earnings are expected to grow with 30.46% in the coming years.
PEG (NY)0.38
PEG (5Y)N/A
EPS Next 2Y39.37%
EPS Next 3Y30.46%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ILU!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ILLUMINA INC

FRA:ILU (7/4/2025, 7:00:00 PM)

82.05

-3.6 (-4.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners107.23%
Inst Owner ChangeN/A
Ins Owners0.17%
Ins Owner ChangeN/A
Market Cap12.99B
Analysts74
Price Target96 (17%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.22%
Min EPS beat(2)-7.76%
Max EPS beat(2)1.33%
EPS beat(4)2
Avg EPS beat(4)-10.12%
Min EPS beat(4)-60.91%
Max EPS beat(4)26.88%
EPS beat(8)6
Avg EPS beat(8)314.25%
EPS beat(12)9
Avg EPS beat(12)229.49%
EPS beat(16)13
Avg EPS beat(16)180.02%
Revenue beat(2)0
Avg Revenue beat(2)-0.57%
Min Revenue beat(2)-0.95%
Max Revenue beat(2)-0.18%
Revenue beat(4)1
Avg Revenue beat(4)-0.53%
Min Revenue beat(4)-1.91%
Max Revenue beat(4)0.91%
Revenue beat(8)3
Avg Revenue beat(8)-0.59%
Revenue beat(12)4
Avg Revenue beat(12)-1.16%
Revenue beat(16)7
Avg Revenue beat(16)0.05%
PT rev (1m)-6.7%
PT rev (3m)-21.3%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-8.95%
EPS NY rev (1m)-0.31%
EPS NY rev (3m)-6.14%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.65%
Revenue NY rev (1m)-0.07%
Revenue NY rev (3m)-2.75%
Valuation
Industry RankSector Rank
PE 28.99
Fwd PE 20.31
P/S 3.53
P/FCF 17.47
P/OCF 15.3
P/B 6.46
P/tB 15.66
EV/EBITDA 13.51
EPS(TTM)2.83
EY3.45%
EPS(NY)4.04
Fwd EY4.92%
FCF(TTM)4.7
FCFY5.72%
OCF(TTM)5.36
OCFY6.53%
SpS23.25
BVpS12.7
TBVpS5.24
PEG (NY)0.38
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.61%
ROE -40.75%
ROCE 19.27%
ROIC 13.57%
ROICexc 18.36%
ROICexgc 30.44%
OM 21.07%
PM (TTM) N/A
GM 66.34%
FCFM 20.2%
ROA(3y)-22.28%
ROA(5y)-10.63%
ROE(3y)-46.16%
ROE(5y)-23.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y-6.48%
ROICexc growth 3YN/A
ROICexc growth 5Y-9.28%
OM growth 3YN/A
OM growth 5Y-11.47%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.07%
GM growth 5Y-1.23%
F-Score6
Asset Turnover0.7
Health
Industry RankSector Rank
Debt/Equity 0.63
Debt/FCF 2.27
Debt/EBITDA 1.21
Cap/Depr 39.37%
Cap/Sales 2.86%
Interest Coverage 250
Cash Conversion 81.37%
Profit Quality N/A
Current Ratio 1.86
Quick Ratio 1.48
Altman-Z 3.69
F-Score6
WACC10.22%
ROIC/WACC1.33
Cap/Depr(3y)66.6%
Cap/Depr(5y)76.75%
Cap/Sales(3y)5.82%
Cap/Sales(5y)5.58%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)278.41%
EPS 3Y-25.65%
EPS 5Y-17.93%
EPS Q2Q%977.78%
EPS Next Y76.08%
EPS Next 2Y39.37%
EPS Next 3Y30.46%
EPS Next 5Y21.99%
Revenue 1Y (TTM)-3.47%
Revenue growth 3Y-1.15%
Revenue growth 5Y4.29%
Sales Q2Q%-3.25%
Revenue Next Year-2.13%
Revenue Next 2Y0.45%
Revenue Next 3Y2.3%
Revenue Next 5Y3.86%
EBIT growth 1Y1675.86%
EBIT growth 3YN/A
EBIT growth 5Y-7.67%
EBIT Next Year26.49%
EBIT Next 3Y15.01%
EBIT Next 5Y12.66%
FCF growth 1Y484.21%
FCF growth 3Y28.14%
FCF growth 5Y-3.38%
OCF growth 1Y334.78%
OCF growth 3Y15.37%
OCF growth 5Y-4.45%